Eltanexor - Karyopharm Therapeutics

Drug Profile

Eltanexor - Karyopharm Therapeutics

Alternative Names: KPT-8602

Latest Information Update: 31 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Karyopharm Therapeutics
  • Class Antineoplastics; Pyrimidines; Small molecules; Triazoles
  • Mechanism of Action Exportin-1 protein inhibitors; Nuclear export inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Colorectal cancer; Multiple myeloma; Myelodysplastic syndromes; Prostate cancer

Most Recent Events

  • 24 May 2018 Karyopharm Therapeutics and Antengene agree to co-promote and co-develop Selinexor in China, Macau, Taiwan, Hong Kong, South Korea and the ASEAN countries
  • 10 Dec 2017 Additional efficacy and adverse events data from a phase I/II trial in Colorectal cancer, Multiple myeloma, Myelodysplastic syndrome and Prostate cancer released by Karyopharm Therapeutics
  • 05 Dec 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top